Lei Ma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lei Ma has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- H. Eric Xu
CAS Key Laboratory of Receptor Research, Center for Structure and Function of Drug Targets, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
1 shared publication Leying Zhu
Guangdong Provincial Key Laboratory of Molecular Target and Clinical Pharmacology, the State Key Laboratory of Respiratory Disease, The Third Affiliated Hospital & School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, China
1 shared publication- Miao Liang
Guangdong Provincial Key Laboratory of Molecular Target and Clinical Pharmacology, the State Key Laboratory of Respiratory Disease, The Third Affiliated Hospital & School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, China
1 shared publication Silin Zhang
Guangdong Provincial Key Laboratory of Molecular Target and Clinical Pharmacology, the State Key Laboratory of Respiratory Disease, The Third Affiliated Hospital & School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, China
1 shared publication- Wei Yi
Guangzhou Medical University
1 shared publication Xianglin Zhou
Guangdong Provincial Key Laboratory of Molecular Target and Clinical Pharmacology, the State Key Laboratory of Respiratory Disease, The Third Affiliated Hospital & School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, China
1 shared publication
Latest Publications
- Open Access
- 13 November 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (46)
Dual-action small-molecule VSP-51-2 ameliorates polycystic ovary syndrome via PPARγ modulation and AKR1C3 inhibition
Polycystic ovary syndrome (PCOS), a prevalent multifactorial endocrine disorder, is inadequately managed by current therapies that fail to concurrently target its core metabolic (insulin resistance) and reproductive (hyperandrogenism) pathologies. We report VSP-51-2, a dual-target lead compound initially engineered as a selective PPARγ modulator that unexpectedly exerts potent uncompetitive inhibition of the androgen-synthesizing enzyme AKR1C3 through a putative allosteric mechanism. In preclinical PCOS models, VSP-51-2 restored regular estrous cyclicity, improved ovarian follicular morphology, enhanced systemic insulin sensitivity, suppressed hyperandrogenism, and did not significantly perturb measured hypothalamic-pituitary-ovarian (HPO) axis hormonal parameters. Mechanistically, it blocks PPARγ phosphorylation at Ser 273 , thereby enhancing adiponectin secretion and GLUT4-mediated glucose uptake, and is predicted to bind a putative allosteric pocket of AKR1C3 to constrain androgen biosynthesis. These findings support VSP-51-2 as a preclinical proof-of-concept compound for a dual-target strategy that addresses metabolic dysfunction and androgen excess through a unified molecular scaffold.
- 13 November 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (46)
Open AccessDual-action small-molecule VSP-51-2 ameliorates polycystic ovary syndrome via PPARγ modulation and AKR1C3 inhibition
Polycystic ovary syndrome (PCOS), a prevalent multifactorial endocrine disorder, is inadequately managed by current therapies that fail to concurrently target its core metabolic (insulin resistance) and reproductive (hyperandrogenism) pathologies. We report VSP-51-2, a dual-target lead compound initially engineered as a selective PPARγ modulator that unexpectedly exerts potent uncompetitive inhibition of the androgen-synthesizing enzyme AKR1C3 through a putative allosteric mechanism. In preclinical PCOS models, VSP-51-2 restored regular estrous cyclicity, improved ovarian follicular morphology, enhanced systemic insulin sensitivity, suppressed hyperandrogenism, and did not significantly perturb measured hypothalamic-pituitary-ovarian (HPO) axis hormonal parameters. Mechanistically, it blocks PPARγ phosphorylation at Ser 273 , thereby enhancing adiponectin secretion and GLUT4-mediated glucose uptake, and is predicted to bind a putative allosteric pocket of AKR1C3 to constrain androgen biosynthesis. These findings support VSP-51-2 as a preclinical proof-of-concept compound for a dual-target strategy that addresses metabolic dysfunction and androgen excess through a unified molecular scaffold.